PMID- 25200403
OWN - NLM
STAT- MEDLINE
DCOM- 20150413
LR  - 20221207
IS  - 1471-230X (Electronic)
IS  - 1471-230X (Linking)
VI  - 14
DP  - 2014 Sep 9
TI  - Factors influencing treatment outcome in patients with gastroesophageal reflux 
      disease: outcome of a prospective pragmatic trial in Asian patients.
PG  - 156
LID - 10.1186/1471-230X-14-156 [doi]
LID - 156
AB  - BACKGROUND: Predicting response to proton pump inhibitor (PPI) treatment can aid 
      the effective management of gastroesophageal reflux disease (GERD). The aim was 
      to investigate the predictors of symptomatic response to pantoprazole in Asian 
      patients with GERD; the first study of its kind in Asian patients. METHODS: Asian 
      patients with GERD symptoms (N = 209) received pantoprazole 40 mg daily for 8 
      weeks in a multinational, prospective, open-label study. Response was assessed 
      using ReQuest. Baseline and demographic factors were examined using logistic 
      regression to determine if they were related to treatment response. RESULTS: 
      Response rates were 44.3% (Week 4) and 63.6% (Week 8) in Asian patients versus 
      60.7% (P < 0.001) and 72.2% (P = 0.010) for the rest of the world. Higher 
      response rates at 8 weeks occurred in patients with erosive reflux disease (ERD; 
      71.3%) versus those with non-erosive reflux disease (NERD) at baseline (48.5%). 
      The presence of ERD (P = 0.0143) and lower ReQuest-GI scores at baseline (P = 
      0.0222) were associated with response. Improvements in quality of life (QoL) and 
      anxiety and depression at 4 and 8 weeks were associated with treatment response 
      (both P < 0.0001). Patient satisfaction correlated with treatment response (P < 
      0.0001), and improvement in anxiety and depression (P < 0.0001) and QoL (P < 
      0.0001). CONCLUSIONS: Asian patients with GERD, especially those with NERD, may 
      have lower response rates to PPIs than Western populations. ERD and less severe 
      gastrointestinal symptoms may help to predict symptomatic responses to PPIs in 
      Asian patients. TRIAL REGISTRATION: ClinicalTrial.gov identifier: NCT00312806.
FAU - Goh, Khean Lee
AU  - Goh KL
FAU - Choi, Kee Don
AU  - Choi KD
FAU - Choi, Myung-Gyu
AU  - Choi MG
FAU - Hsieh, Tsai-Yuan
AU  - Hsieh TY
FAU - Jung, Hwoon-Yong
AU  - Jung HY
FAU - Lien, Han-Chung
AU  - Lien HC
FAU - Menon, Jayaram
AU  - Menon J
FAU - Mesenas, Steven
AU  - Mesenas S
FAU - Park, Hyojin
AU  - Park H
FAU - Sheu, Bor-Shyang
AU  - Sheu BS
FAU - Wu, Justin Cy
AU  - Wu JC
AD  - The Chinese University of Hong Kong, Shatin, Hong Kong SAR, Republic of China. 
      justinwu@cuhk.edu.hk.
LA  - eng
SI  - ClinicalTrials.gov/NCT00312806
PT  - Journal Article
PT  - Pragmatic Clinical Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20140909
PL  - England
TA  - BMC Gastroenterol
JT  - BMC gastroenterology
JID - 100968547
RN  - 0 (2-Pyridinylmethylsulfinylbenzimidazoles)
RN  - 0 (Proton Pump Inhibitors)
RN  - D8TST4O562 (Pantoprazole)
SB  - IM
MH  - 2-Pyridinylmethylsulfinylbenzimidazoles/*therapeutic use
MH  - Adult
MH  - Anxiety/psychology
MH  - *Asian People
MH  - Depression/psychology
MH  - Female
MH  - Gastroesophageal Reflux/*drug therapy/psychology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pantoprazole
MH  - Patient Satisfaction
MH  - Prospective Studies
MH  - Proton Pump Inhibitors/*therapeutic use
MH  - Quality of Life/psychology
MH  - Surveys and Questionnaires
MH  - Treatment Outcome
PMC - PMC4176852
EDAT- 2014/09/10 06:00
MHDA- 2015/04/14 06:00
PMCR- 2014/09/09
CRDT- 2014/09/10 06:00
PHST- 2013/06/14 00:00 [received]
PHST- 2014/08/08 00:00 [accepted]
PHST- 2014/09/10 06:00 [entrez]
PHST- 2014/09/10 06:00 [pubmed]
PHST- 2015/04/14 06:00 [medline]
PHST- 2014/09/09 00:00 [pmc-release]
AID - 1471-230X-14-156 [pii]
AID - 1184 [pii]
AID - 10.1186/1471-230X-14-156 [doi]
PST - epublish
SO  - BMC Gastroenterol. 2014 Sep 9;14:156. doi: 10.1186/1471-230X-14-156.